Inventor · disambiguated record
Lamya Shihabuddin
Also filed as: SHIHABUDDIN LAMYA · SHIHABUDDIN LAMYA S
28 granted patents·24 pending applications·249 citations·filing 2007–2025
97Inventor score
Files withGENZYME CORP31IONIS PHARMACEUTICALS INC6BIOGEN MA INC4DODGE JAMES3BRIGHAM & WOMENS HOSPITAL2
Top patents by PatentIndex Score
52 records- 0198US11911440B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted Feb 27, 2024·5 cites·20 claims
- 0297US11975043B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted May 7, 2024·3 cites·33 claims
- 0397US9717750B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2015·Granted Aug 1, 2017·26 cites·42 claims
- 0497US8980853B2Compositions and methods for modulation of SMN2 splicing in a subjectBENNETT C FRANK·Filed 2010·Granted Mar 17, 2015·48 cites·4 claims
- 0596US10369193B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2016·Granted Aug 6, 2019·17 cites·13 claims
- 0695US9415119B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2015·Granted Aug 16, 2016·13 cites·7 claims
- 0795US9273315B2Modulation of huntingtin expressionISIS PHARMACEUTICALS INC·Filed 2014·Granted Mar 1, 2016·19 cites·14 claims
- 0893US10837016B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 17, 2020·2 cites·16 claims
- 0993US9034836B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersDODGE JAMES·Filed 2008·Granted May 19, 2015·27 cites·9 claims
- 1092US12350311B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2024·Granted Jul 8, 2025·0 cites·21 claims
- 1192US11253485B2Slow intraventricular deliveryGENZYME CORP·Filed 2019·Granted Feb 22, 2022·4 cites·15 claims
- 1291US10821154B2Compositions and methods for treating spinal muscular atrophyGENZYME CORP·Filed 2013·Granted Nov 3, 2020·7 cites·19 claims
- 1391US10213494B2Treatment of synucleinopathiesBRIGHAM & WOMENS HOSPITAL INC·Filed 2016·Granted Feb 26, 2019·11 cites·8 claims
- 1490US10619158B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Apr 14, 2020·2 cites·16 claims
- 1590US8926967B2Intraventricular enzyme delivery for lysosomal storage diseasesDODGE JAMES·Filed 2008·Granted Jan 6, 2015·13 cites·29 claims
- 1689US9683236B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2016·Granted Jun 20, 2017·5 cites·16 claims
- 1789US8454954B2Treatment of synucleinopathiesSCHLOSSMACHER MICHAEL·Filed 2008·Granted Jun 4, 2013·20 cites·11 claims
- 1888US12241078B2AAV vectors for retinal and CNS gene therapyGENZYME CORP·Filed 2021·Granted Mar 4, 2025·1 cites·37 claims
- 1988US2024033323A1Gene Therapy For Neurodegenerative DisordersGENZYME CORP·Filed 2023·Application pending·0 cites
- 2088US2025288644A1Gene Therapy For Neurodegenerative DisordersGENZYME CORP·Filed 2025·Application pending·0 cites
- 2187US11421231B2Modulation of Huntington expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·1 cites·16 claims
- 2287US2024238326A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2386US10080783B2Intraventricular enzyme delivery for lysosomal storage diseasesGENZYME CORP·Filed 2014·Granted Sep 25, 2018·6 cites·22 claims
- 2485US10744210B2Gene therapy for spinal cord disordersDODGE JAMES·Filed 2007·Granted Aug 18, 2020·8 cites·10 claims
- 2585US8906873B2Modulation of huntingtin expressionHUNG GENE·Filed 2010·Granted Dec 9, 2014·8 cites·8 claims
- 2684US10202603B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Feb 12, 2019·2 cites·16 claims
- 2782US12297431B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2022·Granted May 13, 2025·0 cites·14 claims
- 2880US12465657B2Enhanced delivery of viral particles to the striatum and cortexGENZYME CORP·Filed 2022·Granted Nov 11, 2025·0 cites·10 claims
- 2978US2023364200A1Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersGENZYME CORP·Filed 2022·Application pending·0 cites
- 3077US2024000886A1Compositions and Methods for Treating Spinal Muscular AtrophyGENZYME CORP·Filed 2023·Application pending·0 cites
- 3177US2023287366A1Gene therapy for niemann-pick disease type aGENZYME CORP·Filed 2023·Application pending·0 cites
- 3275US11554161B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersGENZYME CORP·Filed 2019·Granted Jan 17, 2023·0 cites·4 claims
- 3375US2020376018A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 3473US2020384076A1Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2020·Application pending·0 cites
- 3572US9314512B2Treatment of synucleinopathiesBRIGHAM & WOMENS HOSPITAL·Filed 2015·Granted Apr 19, 2016·1 cites·11 claims
- 3672US2021228692A1Intraventricular enzyme delivery for lysosomal storage diseasesGENZYME CORP·Filed 2020·Application pending·0 cites
- 3771US2022370348A1Slow intraventricular deliveryGENZYME CORP·Filed 2022·Application pending·0 cites
- 3871US2025320522A1Aav vectors for retinal and cns gene therapyGENZYME CORP·Filed 2025·Application pending·0 cites
- 3966US2021121523A1Compositions and methods for treating spinal muscular atrophyGENZYME CORP·Filed 2020·Application pending·0 cites
- 4062US2019030058A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 4162US2009123451A1Slow intraventricular deliveryGENZYME CORP·Filed 2008·Application pending·0 cites
- 4262US2021008227A1Gene therapy for spinal cord disordersGENZYME CORP·Filed 2020·Application pending·0 cites
- 4360US9101623B2Treatment of synucleinopathiesBRIGHAM & WOMENS HOSPITAL·Filed 2013·Granted Aug 11, 2015·0 cites·11 claims
- 4460US2009117156A1Gene therapy for niemann-pick disease type aGENZYME CORP·Filed 2008·Application pending·0 cites
- 4560US2019083582A1Intraventricular enzyme delivery for lysosomal storage diseasesGENZYME CORP·Filed 2018·Application pending·0 cites
- 4658US2020080066A1Gene therapy for niemann-pick disease type aGENZYME CORP·Filed 2019·Application pending·0 cites
- 4757US2020197374A1Methods for treating proteinopathiesGENZYME CORP·Filed 2020·Application pending·0 cites
- 4855US2013287736A1Gene therapy for neurodegenerative disordersPASSINI MARCO A·Filed 2011·Application pending·0 cites
- 4950US2016067312A1Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersGENZYME CORP·Filed 2015·Application pending·0 cites
- 5049US2019111157A1Enhanced delivery of viral particles to the striatum and cortexGENZYME CORP·Filed 2016·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →